ATP-binding cassette (ABC) drug transporters in the developing blood–brain barrier: role in fetal brain protection
- 11 July 2022
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (8) , 1-18
Abstract
The blood–brain barrier (BBB) provides essential neuroprotection from environmental toxins and xenobiotics, through high expression of drug efflux transporters in endothelial cells of the cerebral capillaries. However, xenobiotic exposure, stress, and inflammatory stimuli have the potential to disrupt BBB permeability in fetal and post-natal life. Understanding the role and ability of the BBB in protecting the developing brain, particularly with respect to drug/toxin transport, is key to promoting long-term brain health. Drug transporters, particularly P-gp and BCRP are expressed in early gestation at the developing BBB and have a crucial role in developmental homeostasis and fetal brain protection. We have highlighted several factors that modulate drug transporters at the developing BBB, including synthetic glucocorticoid (sGC), cytokines, maternal infection, and growth factors. Some factors have the potential to increase expression and function of drug transporters and increase brain protection (e.g., sGC, transforming growth factor [TGF]-β). However, others inhibit drug transporters expression and function at the BBB, increasing brain exposure to xenobiotics (e.g., tumor necrosis factor [TNF], interleukin [IL]-6), negatively impacting brain development. This has implications for pregnant women and neonates, who represent a vulnerable population and may be exposed to drugs and environmental toxins, many of which are P-gp and BCRP substrates. Thus, alterations in regulated transport across the developing BBB may induce long-term changes in brain health and compromise pregnancy outcome. Furthermore, a large portion of neonatal adverse drug reactions are attributed to agents that target or access the nervous system, such as stimulants (e.g., caffeine), anesthetics (e.g., midazolam), analgesics (e.g., morphine) and antiretrovirals (e.g., Zidovudine); thus, understanding brain protection is key for the development of strategies to protect the fetal and neonatal brain.Keywords
Funding Information
- Canadian Institutes of Health Research (FDN-148368)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.370196/2019-00)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (10578/2020-5)
This publication has 216 references indexed in Scilit:
- Prenatal Endotoxemia and Placental Drug Transport in The Mouse: Placental Size-Specific EffectsPLOS ONE, 2013
- Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood–Brain Barrier: A Case Study Examining Sorafenib Efflux ClearanceMolecular Pharmaceutics, 2012
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Pericytes are required for blood–brain barrier integrity during embryogenesisNature, 2010
- Maternal glucocorticoid exposure alters tight junction protein expression in the brain of fetal sheepAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinibBritish Journal of Cancer, 2009
- Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrierAmerican Journal of Physiology-Cell Physiology, 2008
- ABC Transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) Expression in the Developing Human CNSNeuropediatrics, 2008
- P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of TopotecanClinical Cancer Research, 2007
- Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5Biochimica et Biophysica Acta (BBA) - General Subjects, 2007